<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730388</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC20.0325</org_study_id>
    <nct_id>NCT04730388</nct_id>
  </id_info>
  <brief_title>ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or</brief_title>
  <acronym>HEPATOFIT</acronym>
  <official_title>Evaluation of the Efficacy and Tolerance of the Association ATEZOLIZUMAB - BEVACIZUMAB in the Treatment of a Locally Advanced Hepatocellular Carcinoma Inoperable or Metastatic in Finistère</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the&#xD;
      treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma&#xD;
      will be followed to observed their safety and the efficacy of this treatment, and to identify&#xD;
      prongnosis factors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 18, 2021</start_date>
  <completion_date type="Anticipated">January 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>predictive factor for progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>progression-free survival = time between treatment initiation and rediologic or clinical progression</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatocellular carcinoma locally advanced or metastatic in first line of systemic treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hepatocellular carcinoma locally advanced or metastatic, non able to be resectable,&#xD;
             with no prior systemic treatment&#xD;
&#xD;
          -  Child Pugh A and ECOG 0 or 1&#xD;
&#xD;
          -  upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be&#xD;
             treated&#xD;
&#xD;
          -  non eligible to receive a locoregional therpay or progressive after this kinf of&#xD;
             treatment&#xD;
&#xD;
          -  with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refuse to participate&#xD;
&#xD;
          -  under legal protection&#xD;
&#xD;
          -  exclusion criteria from the tempory utilisation authorization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Guillaume Poureau, MD</last_name>
    <phone>0298223740</phone>
    <email>pierre-guillaume.poureau@chu-brest.fr</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ATEZOLIZUMAB, BEVACIZUMAB , Advanced hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

